write an apa paper for me nursing reflective essay dissertation sampling methods homework help with song lyrics custom essay experts
Skip to main content

Nanoparticles for the targeted treatment of neovascular ocular diseases

Ref-Nr: TA-B79130


Kurzfassung

  • systemic therapy instead of intravitreal antibody injections
  • a single systemic injection cured retinopathy of prematurity in mouse model
  • causal treatment of all neovascular ocular diseases

Hintergrund

Every year diabetic retinopathy, wet age-related macular degeneration, and retinopathy of prematurity causes millions of cases of blindness and vision impairment. Their pathogenesis shares a complex triad of neovascularization, inflammation and immune system activation that is fueled by factors originating from the retinal pigment epithelium (RPE). However, despite its pivotal role there is no therapeutic tool to specifically deliver drugs to the RPE.
Simple means of systemic drug administration fail since dosing regimens that would build up relevant RPE levels would trigger severe side effects due to the unfavorable drug distribution in the organism. The alternative, intraocular drug therapy, also suffers from a number of shortcomings especially due to the lack of cell specificity and invasive way of administration. Today´s standard therapy for all neovascular ocular diseases, the repeated intravitreal anti-VEGF antibody injections is limited to suppression of neovascularization, accompanied by serious local and systemic side effects, resulting in patient discomfort and lack of compliance.


Bilder & Videos


Lösung

Here, lipid nanoparticles were designed to transport drugs to the RPE following intravenous injection that address all three pathomechanisms. A single injection of Cyclosporin A loaded nanoparticles cured retinopathy of prematurity in a mouse model. By counteracting neovascularization, dampening inflammation and normalizing levels of growth factors, growth factor receptors and cytokines, this nanotherapeutic paves the way for the causal treatment of all neovascular ocular diseases.


Anwendungsbereiche

Causal systemic treatment of neovascular ocular diseases.

@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-536859905 -1073732485 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin-top:0cm; margin-right:0cm; margin-bottom:10.0pt; margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; mso-bidi-font-size:12.0pt; font-family:"Calibri",sans-serif; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:11.0pt; mso-ansi-font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-fareast-language:EN-US;}.MsoPapDefault {mso-style-type:export-only; margin-bottom:10.0pt; line-height:115%;}div.WordSection1 {page:WordSection1;}


Bayerische Patentallianz GmbH


089 5480177-0
kontakt@baypat.de
www.baypat.de
Adresse
Destouchesstr. 68
80796 München



Entwicklungsstand

Machbarkeit


Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen